{"id":"NCT01830140","sponsor":"Allergan","briefTitle":"A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2013-04-12","resultsPosted":"2015-05-06","lastUpdate":"2015-05-06"},"enrollment":466,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Bimatoprost 0.01%","otherNames":["LUMIGAN® 0.01%"]},{"type":"DRUG","name":"Bimatoprost 0.03%","otherNames":["LUMIGAN® 0.03%"]}],"arms":[{"label":"Bimatoprost 0.01%","type":"EXPERIMENTAL"},{"label":"Bimatoprost 0.03%","type":"ACTIVE_COMPARATOR"}],"summary":"This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).","primaryOutcome":{"measure":"Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye","timeFrame":"Baseline, 6 Weeks","effectByArm":[{"arm":"Bimatoprost 0.01%","deltaMin":34.3,"sd":null},{"arm":"Bimatoprost 0.03%","deltaMin":39.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":233},"commonTop":["Conjunctival Hyperaemia","Eye Pruritus"]}}